Published by Global Banking & Finance Review®
Posted on April 29, 2025
1 min readLast updated: January 24, 2026
AstraZeneca will keep its 2025 sales forecast if US tariffs on EU pharma products align with other sectors, despite a Q1 revenue miss.
LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they are in line with rates for other sectors.
Pascal Soriot was speaking to journalists on a call after the company reported first-quarter results in which revenues missed analyst expectations, pushing shares down by more than 4%.
(Reporting by Maggie Fick and Pushkala Aripaka, Editing by Louise Heavens)
The main topic is AstraZeneca's decision to maintain its 2025 sales forecast despite potential US tariffs on EU-made pharmaceutical products.
AstraZeneca's shares fell by more than 4% after reporting Q1 results that missed analyst expectations.
Pascal Soriot is the CEO of AstraZeneca.
Explore more articles in the Headlines category
